Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Wynne

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Bioorganic & Medicinal Chemistry|October 27, 2005
Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase BIan Collins, John Caldwell, Tatiana Fonseca, et al.
Journal of Medicinal Chemistry|October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitorsMichael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Journal of Medicinal Chemistry|February 16, 2010
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)Tatiana McHardy, John J Caldwell, Kwai-Ming Cheung, et al.
Oncotarget|September 28, 2013
The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug designSylvain Couty, Isaac M Westwood, Andrew Kalusa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Bioorganic & Medicinal Chemistry|October 27, 2005
Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase BIan Collins, John Caldwell, Tatiana Fonseca, et al.
Journal of Medicinal Chemistry|October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitorsMichael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Journal of Medicinal Chemistry|February 16, 2010
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)Tatiana McHardy, John J Caldwell, Kwai-Ming Cheung, et al.
Oncotarget|September 28, 2013
The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug designSylvain Couty, Isaac M Westwood, Andrew Kalusa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugsMike I Walton, Paul D Eve, Angela Hayes, et al.
Oncotarget|August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaMike I Walton, Paul D Eve, Angela Hayes, et al.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Pageof 10